127 related articles for article (PubMed ID: 187940)
1. Limitations of an extinction approach to narcotic antagonist treatment.
Meyer R; Randall R; Barrington C; Mirin S; Greenberg I
NIDA Res Monogr; 1976 Sep; (9):123-35. PubMed ID: 187940
[No Abstract] [Full Text] [Related]
2. The clinical usefulness of narcotic antagonists: implications of behavioral research.
Meyer RE; Mirin SM; Altman JL
Am J Drug Alcohol Abuse; 1975; 2(3-4):417-32. PubMed ID: 179316
[No Abstract] [Full Text] [Related]
3. Opiate antagonists and the modification of heroin self-administration behavior in man: an experimental study.
Altman JL; Meyer RE; Mirin SM; McNamee HB
Int J Addict; 1976; 11(3):485-99. PubMed ID: 184054
[TBL] [Abstract][Full Text] [Related]
4. Methadone maintenance and narcotic blocking drugs.
Wikler A
Int J Addict; 1977 Oct; 12(7):851-6. PubMed ID: 201577
[TBL] [Abstract][Full Text] [Related]
5. A behavioral paradigm for the evaluation of narcotic antagonists.
Meyer RE; Mirin SM; Altman JL; McNamee HB
Arch Gen Psychiatry; 1976 Mar; 33(3):371-7. PubMed ID: 944026
[TBL] [Abstract][Full Text] [Related]
6. Effect of chronic delivery of the Toll-like receptor 4 antagonist (+)-naltrexone on incubation of heroin craving.
Theberge FR; Li X; Kambhampati S; Pickens CL; St Laurent R; Bossert JM; Baumann MH; Hutchinson MR; Rice KC; Watkins LR; Shaham Y
Biol Psychiatry; 2013 Apr; 73(8):729-37. PubMed ID: 23384483
[TBL] [Abstract][Full Text] [Related]
7. Naltrexone implants as treatment for heroin dependence: part II.
Wodak A; Graham R
Addict Biol; 2005 Jun; 10(2):202; author reply 202-4. PubMed ID: 16201030
[No Abstract] [Full Text] [Related]
8. Naltrexone implants as treatment for heroin dependence: part I.
Byrne A; Graham G; Hallinan R; Murnion B
Addict Biol; 2005 Jun; 10(2):201; author reply 201-2. PubMed ID: 16191674
[No Abstract] [Full Text] [Related]
9. Aftercare on narcotic antagonists: prospects and problems.
Rawlins M; Randall M
Int J Addict; 1976; 11(3):501-11. PubMed ID: 184055
[TBL] [Abstract][Full Text] [Related]
10. NIDA's naltrexone research program.
Julius D
NIDA Res Monogr; 1976 Sep; (9):5-11. PubMed ID: 187943
[No Abstract] [Full Text] [Related]
11. Rapid heroin detoxification under general anesthesia.
Laheij RJ; Krabbe PF; de Jong CA
JAMA; 2000 Mar; 283(9):1143. PubMed ID: 10703775
[No Abstract] [Full Text] [Related]
12. The theoretical basis of narcotic addiction treatment with narcotic antagonists.
Wikler A
NIDA Res Monogr; 1976 Sep; (9):119-22. PubMed ID: 1004530
[No Abstract] [Full Text] [Related]
13. Methadone maintenance and narcotic blocking drugs. Appendix.
Wikler A
Int J Addict; 1977 Oct; 12(7):869-81. PubMed ID: 338517
[TBL] [Abstract][Full Text] [Related]
14. Analysis and modification of opiate reinforcement.
Meyer RE; McNamee HB; Mirin SM; Altman JL
Int J Addict; 1976; 11(3):467-84. PubMed ID: 184053
[TBL] [Abstract][Full Text] [Related]
15. [Surprising conclusion by the SBU concerning the benefits of naltrexone in the treatment of heroin dependence].
Heilig M
Lakartidningen; 2002 Jan; 99(3):200-4. PubMed ID: 11838078
[No Abstract] [Full Text] [Related]
16. Lack of information in naltrexone study.
Rastegar DA
Arch Gen Psychiatry; 2007 Jul; 64(7):865; author reply 865. PubMed ID: 17606820
[No Abstract] [Full Text] [Related]
17. Naltrexone in methadone maintenance patients electing to become "drug free".
Haas N; Ling W; Holmes E; Blakis M; Litaker M
NIDA Res Monogr; 1976 Sep; (9):70-3. PubMed ID: 794723
[No Abstract] [Full Text] [Related]
18. Opiate agonist treatment for addiction.
Newman RG
Lancet; 2008 Dec; 372(9654):1951-2; author reply 1952. PubMed ID: 19059045
[No Abstract] [Full Text] [Related]
19. Realistic goals for antagonist therapy.
Martin WR
Am J Drug Alcohol Abuse; 1975; 2(3-4):353-6. PubMed ID: 1227296
[No Abstract] [Full Text] [Related]
20. Narcotic antagonists in opiate dependence.
Fink M
Science; 1970 Sep; 169(3949):1005-6. PubMed ID: 4914724
[No Abstract] [Full Text] [Related]
[Next] [New Search]
